Evidence map›Paper›PMID 24942544›Full record

ArticleJournal of neuroinflammation2014

Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome.

Milo Careaga, Tamanna Noyon, Kirin Basuta, Judy Van de Water, Flora Tassone, Randi J Hagerman, Paul Ashwood

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction.Frontiers in cell and developmental biology · 2020
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Milo Careaga
Tamanna Noyon
Kirin Basuta
Judy Van de Water
Flora Tassone
Randi J Hagerman
Paul AshwoodDepartment of Medical Microbiology and Immunology, and the MIND Institute, UC Davis, 2805, 50th Street, Sacramento, CA 95817, USA. pashwood@ucdavis.edu.
University of California Davis Medical Center · USUniversity of California, Davis · US

Funding

Restoring FMRP Phenotypes Frpm Temporal Regional and Splice- Isoforms VarationsP30HD002274 · NICHD · UNIVERSITY OF WASHINGTON · PI GURALNICK, MICHAEL J · 1985 to 2013
$33.6M
GENOTYPE/PHENOTYPE RELATIONSHIPS IN FRAGILE X FAMILIESR01HD036071 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI PAUL J HAGERMAN, RANDI J. HAGERMAN · 1998 to 2026
$13.8M
UC Davis Center for Children's Environmental Health (CCEH)P01ES011269 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI VAN DE WATER, JUDY A. · 2001 to 2018
$12.5M
Rodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI VAN DE WATER, JUDY A. · 2013 to 2019
$8.5M
NICHD NIH HHS HD02274NICHD NIH HHS HD036071NICHD NIH HHS R01 HD036071NICHD NIH HHS U54 HD079125NIEHS NIH HHS P01 ES011269
6 · The paper itself

Abstract

backgroundFragile X syndrome (FXS) is the leading cause of inheritable intellectual disability in male children, and is predominantly caused by a single gene mutation resulting in expanded trinucleotide CGG-repeats within the 5' untranslated region of the fragile X mental retardation (FMR1) gene. Reports have suggested the presence of immune dysregulation in FXS with evidence of altered plasma cytokine levels; however, no studies have directly assessed functional cellular immune responses in children with FXS. In order to ascertain if immune dysregulation is present in children with FXS, dynamic cellular responses to immune stimulation were examined.

methodsPeripheral blood mononuclear cells (PBMC) were from male children with FXS (n=27) and from male aged-matched typically developing (TD) controls (n=8). PBMC were cultured for 48 hours in media alone or with lipopolysaccharides (LPS; 1 μg/mL) to stimulate the innate immune response or with phytohemagglutinin (PHA; 8 μg/mL) to stimulate the adaptive T-cell response. Additionally, the group I mGluR agonist, DHPG, was added to cultures to ascertain the role of mGluR signaling in the immune response in subject with FXS. Supernatants were harvested and cytokine levels were assessed using Luminex multiplexing technology.

resultsChildren with FXS displayed similar innate immune response following challenge with LPS alone when compared with TD controls; however, when LPS was added in the presence of a group I mGluR agonist, DHPG, increased immune response were observed in children with FXS for a number of pro-inflammatory cytokines including IL-6 (P=0.02), and IL-12p40 (P<0.01). Following PHA stimulation, with or without DHPG, no significant differences between subjects with FXS and TD were seen.

conclusionsIn unstimulated cultures, subjects with FXS did not display altered dynamic immune response to LPS or PHA alone; however, subjects with FXS showed an altered response to co-current stimulation of LPS and DHPG, such that subjects with FXS failed to inhibit production of pro-inflammatory cytokines, suggesting a role of group I mGluR signaling in innate immune responses in FXS.

Indexed as

Case-Control StudiesCells, CulturedChildChild, PreschoolCytokinesExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansLeukocytes, MononuclearLipopolysaccharidesMaleMethoxyhydroxyphenylglycolMitogensPhytohemagglutinins3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine3,4-dihydroxyphenylglycolCytokinesExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsFragile X Messenger Ribonucleoprotein 1Lipopolysaccharidesmetabotropic glutamate receptor type 1MethoxyhydroxyphenylglycolMitogensPhytohemagglutininsPyridinesReceptors, Metabotropic GlutamateThiazoles

Identifiers

PMID24942544
PMCPMC4107617
OpenAlexW2161322144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.